NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/16/2024
Back to search
Official data from USPTO
G GARONIT PHARMACEUTICAL
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
31
Latest update
01/16/2024
Trademark type
Combined
Nice classes
1
Filing date
06/03/2022
Registration date
01/16/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/16/2024
Last transaction
01/16/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
2023-10-00
First use in commerce
2023-10-00
Drawing code
3
Owner type
03
Owner location
Fairfield, NJ
Examiner
BROWNING, KATHRYN
Law office
N60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a hexagon having a stylized capital letter G in the middle of the hexagon with the word "GARONIT" in all-caps appearing below the hexagon and the word "PHARMACEUTICAL" in all-caps appearing beneath "GARONIT" in a smaller font.
Holders and representatives
Holders
Garonit Pharmaceutical, Inc.
Representatives
Nancy A. Del Pizzo Rivkin Radler LLP
Technical classification
Nice Classes
Class 1
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Glycerine for use in the manufacture of pharmaceuticals and cosmetics; N-acetyl-d-glucosamine for use in the manufacture of cosmetics and anti-aging moisturizers used as cosmetics; Chemicalschlorhexidiene gluconate as a raw chemical for use in the manufacture of antiseptics
Publications
History of USPTO decisions and trademark events.
31 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
01/16/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
12/13/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
12/12/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
12/12/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
12/12/2023
IUAF
USE AMENDMENT FILED
12/04/2023
EISU
TEAS STATEMENT OF USE RECEIVED
12/04/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
08/15/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/20/2023
PUBO
PUBLISHED FOR OPPOSITION
06/20/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/31/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/18/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
05/18/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/18/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
05/18/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/18/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/21/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/21/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/21/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/31/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
03/31/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/31/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/31/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/21/2023
GNRT
NON-FINAL ACTION E-MAILED
03/21/2023
CNRT
NON-FINAL ACTION WRITTEN
03/21/2023
DOCK
ASSIGNED TO EXAMINER
03/20/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/15/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/14/2022
NWAP
NEW APPLICATION ENTERED
06/07/2022
Continuous trademark protection
Get notified about every new filing that threatens G GARONIT PHARMACEUTICAL or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.